Core Viewpoint - The company, Zhifei Biological, has received a clinical trial application acceptance notice for its modified Ankara vaccine for monkeypox, marking a significant breakthrough in its vaccine development efforts [1] Group 1: Clinical Trial Acceptance - Zhifei Longkema, a wholly-owned subsidiary of Zhifei Biological, has developed a modified Ankara vaccine for monkeypox, which has been accepted for clinical trial by the National Medical Products Administration [1] - The acceptance number for the clinical trial application is CXSL2501083, allowing the company to proceed with trials if no negative feedback is received within 60 days [1] Group 2: Vaccine Technology and Safety - The vaccine utilizes a live attenuated vaccine technology route, employing the modified Ankara strain, which cannot effectively replicate in human cells, ensuring high safety [1] - This development is seen as a key achievement in the company's focus on innovative technology and enhancing core capabilities [1] Group 3: Strategic Implications - The acceptance of the clinical trial application is expected to enhance the company's long-term stable development and improve China's independent innovation capabilities in major infectious disease prevention [1] - Successful progress in this project will diversify the company's vaccine offerings, improve its product portfolio, and strengthen its market position [1]

Core Viewpoint - The company has received a clinical trial application acceptance notice for its modified Ankara vaccinia virus (MVA) monkeypox live attenuated vaccine, marking a significant breakthrough in its vaccine development efforts [1] Group 1: Clinical Trial Development - The clinical trial application for the modified MVA monkeypox vaccine was accepted by the National Medical Products Administration, allowing the company to proceed with trials if no objections are raised within 60 days [1] - The vaccine utilizes a modified Ankara strain that cannot effectively replicate in human cells, ensuring high safety levels and preventing secondary transmission [1] Group 2: Strategic Implications - This acceptance signifies a key breakthrough in the company's focus on innovative technologies and core competencies in addressing emerging infectious diseases [1] - Successful progress in this project is expected to enhance the company's vaccine portfolio, improve product layout, and strengthen its market position [1]